


# PRC



## Incidence and impact of cancer pain

Augusto Caraceni  
Director Palliative Care, Pain Therapy and  
Rehabilitation  
**National Cancer Institute of Milan Italy**

# Pain prevalence

- in **cancer patients** :
  - After curative treatment = 33% (survivors ?)
  - Undergoing anticancer treatment = 59%
  - With Advanced metastatic = 70%
  - In the last 3 months of life = 83%
  - All stages > 50%

*van den Beuken-van Everdigen MHJ, Ann Oncology 2007; 18: 1437*

*Higginson I et al Epidemiology of pain in cancer In Hanna M, Zylicz eds. Cancer pain Springer Verlag London 2013 pp 5-23*

# Estimated cancer pain impact


Disease state	population	Total	Estimated pain prevalence
Projected cancer deaths 2016	EU countries (28 , 2013)	1. 359.500	(83%) 1.128.850
5 year Prevalent cancer cases	Northern Southern and Western Europe	6.175.900	(50%) 3.879.000
5 year prevalent cancer cases	Central and Eastern Europe	2.289.000	(50%) 1.144.500

*Bray et al Int J Cancer 2013, Malvezzi et al Ann Oncol 2016*

**Cancer pain interference with quality of life: scores from 0 to 10 where 10 is the maximum interference with quality of life domains in 436 patients (median values, lower and upper percentiles)**

	<b>More severe pain</b>	<b>Less severe pain</b>	
General activity	8 (5–10)	7 (3–8.5)	0.002
Mood	7 (4–8)	6 (2–8)	n.s.
Walking activity	7 (3–9)	5 (2–8)	0.0012
Normal work	10 (7–10)	9 (5–10)	0.0443
Relations	5 (1.5–7)	5 (1–7)	n.s.
Sleep	5 (2–8)	5 (1–8)	n.s.
Life enjoyment	7 (4–9)	7 (3–9)	n.s.

*Caraceni et al Pub Med 2004*



Sistema Sanitario  Regione Lombardia



## Data are insufficient

- For how long do different cancer populations suffer of significant pain ?
- Pain is the most feared symptom of cancer
- Pain announces disease progression and shortening of life expectancy

**AT THE SAME TIME**

- Pain is undertreated in 31.8% of patients

*Greco MT et al J Clin Oncol 2014*

# Perspectives

- More high quality epidemiological data (cancer registries, high resolution studies and clinical records)
- Implementation of cancer pain guidelines\*
- Clinical research in pain and palliative care and oncology not valued enough by European funding agencies
- More integration between oncology and palliative care

*\*Caraceni et al EAPC guidelines Lancet Oncology 2012*